Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing.

ABSTRACT:

Background

Venous thromboembolism (VTE) frequently occurs in hospitalized patients with coronavirus disease 2019 (COVID-19). The optimal dose of anticoagulation for thromboprophylaxis in COVID-19 is unknown.

Aims

To report VTE incidence and bleeding before and after implementing a hospital-wide intensified thromboprophylactic protocol in patients with COVID-19.

Methods

On March 31, 2020, we implemented an intensified thromboprophylactic protocol consisting of 50 IU anti-Xa low molecular weight heparin (LMWH)/kg once daily at the ward, twice daily at the intensive care unit (ICU). We included all patients hospitalized in a tertiary care hospital with symptomatic COVID-19 between March 7 and July 1, 2020. The primary outcome was the incidence of symptomatic or subclinic

SUBMITTER: Engelen MM 

PROVIDER: S-EPMC8980774 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature